Matthew Ronsheim - Feb 20, 2024 Form 4 Insider Report for Innoviva, Inc. (INVA)

Role: Officer
Signature: /s/ Matthew Ronsheim
Stock symbol: INVA
Transactions as of: Feb 20, 2024
Transactions value $: -$12,751
Form type: 4
Date filed: 2/22/2024, 09:31 PM
Previous filing: Jan 22, 2024
Next filing: Mar 7, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INVA	Common Stock	Tax liability	-$12.8K	-807	-2.8%	$15.80	28K	Feb 20, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.

Remarks:

Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.